Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 133, Issue -, Pages 76-86Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2018.08.001
Keywords
Bacteriophages (Phages); Inhaled phage therapy; Antibiotic-resistant bacteria; Formulation; Biopharmaceutics; Inhalation; Respiratory infection
Categories
Funding
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R33AI121627]
- National Health and Medical Research Council [APP1140617]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R33AI121627] Funding Source: NIH RePORTER
Ask authors/readers for more resources
A respiratory infection caused by antibiotic-resistant bacteria can be life-threatening. In recent years, there has been tremendous effort put towards therapeutic application of bacteriophages (phages) as an alternative or supplementary treatment option over conventional antibiotics. Phages are natural parasitic viruses of bacteria that can kill the bacterial host, including antibiotic-resistant bacteria. Inhaled phage therapy involves the development of stable phage formulations suitable for inhalation delivery followed by preclinical and clinical studies for assessment of efficacy, pharmacokinetics and safety. We presented an overview of recent advances in phage formulation for inhalation delivery and their efficacy in acute and chronic rodent respiratory infection models. We have reviewed and presented on the prospects of inhaled phage therapy as a complementary treatment option with current antibiotics and as a preventative means. Inhaled phage therapy has the potential to transform the prevention and treatment of bacterial respiratory infections, including those caused by antibiotic-resistant bacteria. (C) 2018 Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available